GlassScriptPhysician profile
Daniel Scott Harnsberger
NPI 1922073808
$2,929.03
in general payments reported to CMS, 2019-2025
45 companies · $408 in 2025
The $408 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $193 · 2021: $320 · 2022: $469 · 2023: $488 · 2024: $824 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $375.55 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $268.55 | 2019-2024 | |
| Myovant Sciences INC. | $264.36 | 2021-2022 | |
| Sage Therapeutics, LLC | $260.44 | 2023-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $256.42 | 2023-2025 | Myfembree, Gemtesa |
| Daiichi Sankyo INC. | $140.05 | 2019-2024 | Injectafer |
| Pfizer INC. | $126.47 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.03 | 2021-2024 | |
| Shield Therapeutics INC | $97.37 | 2023-2024 | Accrufer |
| Exeltis, USA INC. | $83.63 | 2022-2024 | Slynd |
| Aspira Women'S Health INC | $81.43 | 2020-2023 | Ova1 |
| Novo Nordisk INC | $72.84 | 2024-2025 | Wegovy |
| Organon LLC | $72.37 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $68.80 | 2019-2023 | Gardasil 9 |
| Millicent US INC | $64.45 | 2022-2025 | Intrarosa, Femlyv |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $63.48 | 2019 | |
| Mayne Pharma Commercial LLC | $62.22 | 2021-2024 | |
| Avion Pharmaceuticals | $42.61 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $39.94 | 2025 | Qelbree |
| Baxter Healthcare | $39.65 | 2023-2025 | Perclot, Seprafilm |
| Channel Medsystems, INC. | $37.61 | 2022 | |
| Roche Diagnostics Corporation | $37.39 | 2020 | |
| Smith+Nephew, INC. | $28.25 | 2023-2024 | Pico |
| Currax Pharmaceuticals LLC | $22.88 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $22.52 | 2019-2020 | |
| Gynesonics, INC. | $19.40 | 2022 | |
| Medtronic, INC. | $18.92 | 2025 | Venaseal |
| Integra Lifesciences Corporation | $18.75 | 2025 | Tenoglide |
| Endo Pharmaceuticals INC. | $15.68 | 2021 | |
| Intuitive Surgical, INC. | $15.65 | 2024 | |
| Ethicon US, LLC | $14.07 | 2024 | Ethicon, Surgicel Nu-Knit, Stratafix |
| Takeda Pharmaceuticals U.S.A., INC. | $13.53 | 2019 | |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
| Allergan, INC. | $13.35 | 2019 | |
| Hologic Sales and Service, LLC | $13.29 | 2024 | Myosure Tissue Removal Device, Novasure |
| Amgen INC. | $13.15 | 2019 | |
| Zyla Life Sciences, INC. | $12.44 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harnsberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.